Cochrane · systematic review · CD015448
LipiFlow for the treatment of dry eye disease
Pucker, AD, Yim, TW, Rueff, E, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 50%Low 5 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
LipiFlow compared with basic warm compresses
Population: people with dry eye
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) LipiFlow vs basic warm compresses | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision, inconsistency |
Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) LipiFlow vs basic warm compresses | SMD 1.31 | 2 studies · 76 participants | Very low Downgraded: risk of bias, imprecision |
Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) LipiFlow vs basic warm compresses | no estimate extracted | 1 study · 46 participants | Very low Downgraded: imprecision, inconsistency |
Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks (lower is favored) LipiFlow vs basic warm compresses | no estimate extracted | NR | Low Downgraded: imprecision |
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks LipiFlow vs basic warm compresses | no estimate extracted | 4 studies · 197 participants | Low Downgraded: imprecision |
LipiFlow compared with thermostatic devices
Population: people with dry eye
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) LipiFlow vs thermostatic devices | no estimate extracted | NR | Very low Downgraded: risk of bias, inconsistency |
Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) LipiFlow vs thermostatic devices | no estimate extracted | 3 studies · 820 participants | Low Downgraded: risk of bias |
Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) LipiFlow vs thermostatic devices | SMD 0.11 | 2 studies · 354 participants | Low Downgraded: imprecision, inconsistency |
Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks (lower is favored) LipiFlow vs thermostatic devices | no estimate extracted | NR | Low Downgraded: imprecision |
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks LipiFlow vs thermostatic devices | no estimate extracted | 4 studies · 445 participants | Very low Downgraded: risk of bias, imprecision |